That is one of the great benefits of dupilumab (Dupixent) – it has a great safety profile. Some people get an injection site ... or in a self-injector pen. It can be given by the patient ...

Moving to Dupixent. First quarter 2025 net product ... t have the insurance and can't afford the copay associated with an injection of an anti-VEGF agent, for example. The government has indicated ...

The Diabetes Injection Pens Market is expected to witness a growth rate of ~7% by 2028. The key factors driving the market are the rising prevalence of diabetes, the growing preference for pens over ...

WEDNESDAY, April 23, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adults and adolescents with chronic spontaneous urticaria.

In pooled data from all three studies, the most common adverse event (≥2%) more frequently observed in patients on Dupixent compared to placebo was injection site reactions. George D. Yancopoulus, M.D ...

The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adults and adolescents with chronic spontaneous urticaria. The approval is for patients 12 years and ...

Sanofi SNY and partner Regeneron REGN announced that the FDA approved Dupixent (dupilumab) for the treatment of chronic spontaneous urticaria (“CSU”) in adults and adolescents aged 12 years ...

SINGAPORE, May 14, 2025 /PRNewswire/ -- The Health Sciences Authority (HSA) has approved Dupixent (dupilumab) for adults as an add-on maintenance treatment for uncontrolled chronic obstructive ...

From breaking news to special features, we're on it! Join the NonStop Local Chord group and always be in the know. WEDNESDAY, April 23, 2025 (HealthDay News) -- The U.S. Food and Drug ...

In 2024, Dupixent sales came in at $14.1 billion, which was an increase of 22% from 2023. Dupixent’s trajectory contributed heavily to Sanofi’s strong quarterly performance.